After Hours Summary: TIVO +14%, WINT +10%, SNPS +8% following earnings/guidance, PGNX +5% and SFLY +3% on S&P600 index addition news... CFMS -39%, MOH -14%, OMCL -10%, HAWK -10%, CAR -7%, SPWR -6%, TRIP -5% following earnings/guidanceAfter Hours Gainers:
Companies trading higher in after hours in reaction to earnings/guidance: CSLT +14.3%, TIVO +13.6%, WINT +9.6%, SNPS +7.5%, QUIK +4.2%, CRY +4.1%, NTAP +4%, NMIH +3%, ABX +2.2%, CSCO +2%, GG +2%, SRCL +1.8%, DENN +1.6%
Companies trading higher in after hours in reaction to news: XTLB +48.4% (continues to surge higher in after hours trade), CVRS +39.3% (Corindus Vascular Robotics announces a distribution agreement w/ a subsidiary of Mitsubishi (MSBHY); includes an initial order for 12 CorPath GRX Systems accompanied by an advance of $2 mln toward the purchase price), HGG +21% (HHGregg confirms plans to explore strategic alternatives), PGNX +5.1% (to join S&P SmallCap 600), RUBI +3.2% (still checking), SFLY +3.1% (to join S&P SmallCap 600), TECK +2.5% (to sell its 70% interest in Haib Minerals to Deep-South Resources), VRX +1.8% (FDA approves Siliq to treat adults with moderate-to-severe plaque psoriasis), FL +1.3% (light volume; increases quarterly dividend and approves a new 3-year $1.2 bln share repurchase program)
After Hours Losers:
Companies trading lower in after hours in reaction to earnings/guidance: CFMS -38.6%, MOH -14%, OMCL -9.8%, HAWK -9.6%, CAR -6.6%, SPWR -6.2%, TRIP -5.2%, CLD -4.6% (also replaces its throughput agreement with Westshore Terminals Limited Partnership), GDDY -4.6%, CF -4.3%, MMLP -4% (prices previously announced public offering of 2,600,000 of common units at a price to the public of $18.00 per unit), LSCC -2.8%, EQIX -2.8%, AEM -2.4%, HOS -2.2%, CC -2.1%, KHC -2%, CYS -1.8%, CBS -1.5%
Companies trading lower in after hours in reaction to news: ACUR -29.5% (to be delisted from the Nasdaq; will begin to trade on the OTCQB on February 23), CRSP -6.3% (CRISPR Therapeutics to host call to provide update on the CRISPR/Cas9 U.S. patent interference proceedings and corresponding U.K. patents tomorrow February 16 at 11am ET), NGL -6.2% (commences an underwritten public offering of 8,000,000 common units; intends to offer $450 mln in aggregate principal amount of senior notes due 2025), NAK -3.5% (ongoing volatility), ATKR -2.4% (commences 8 mln common stock offering by selling stockholder), CNC -2.3% (MOH earnings/guidance sympathy), EVOK -2.1% (intends to offer and sell shares of its common stock in a 'firm commitment' underwritten public offering), HTZ -1.6% (CAR sympathy), TRU -1.2% (commences 19.85 mln common stock offering by Selling Stockholders), FRSH -0.9% (announces a strategic realignment of resources aimed at better supporting franchise-owners and field staff while reducing overall SG&A expenses; expects to achieve annual cost savings of $1.5 mln), HOLX 0% (FDA has granted PMA approval for its HCV assay for quantitation of HCV viral load and confirming active HCV infection on the fully automated Panther system)
SunPower earnings weakness is weighing on solar names: VSLR -1.5%, FSLR -1.2%, JKS -0.5%, CSIQ -0.4%
- Reports Q4 (Dec) earnings of $0.85 per share, $0.01 better than the Capital IQ Consensus of $0.84; revenues rose 47.2% year/year to $5.46 bln vs the $4.89 bln Capital IQ Consensus.
- In the 2016 fourth quarter, worldwide comparable systemwide constant dollar RevPAR increased 0.8 percent (a 0.3 percent increase using actual dollars). North American comparable systemwide constant dollar RevPAR increased 1.1 percent (a 1.1 percent increase using actual dollars), and international comparable systemwide constant dollar RevPAR increased 0.2 percent (a 1.4 percent decline using actual dollars) for the same period. These RevPAR growth statistics compare the fourth quarter of 2016 to combined comparable systemwide RevPAR for the fourth quarter of 2015.
- Co issues in-line guidance for Q1, sees EPS of $0.87-0.91 vs. $0.91 Capital IQ Consensus Estimate; sees total fee revenue of $740 million to $750 million
- For the 2017 first quarter, Marriott expects comparable systemwide RevPAR on a constant dollar basis for the combined company will increase 1 to 3 percent in North America and worldwide. Outside North America, the company expects comparable systemwide RevPAR on a constant dollar basis for the combined company will increase 1 to 2 percent. The company's RevPAR guidance for the first quarter reflects the benefit of the U.S. Presidential inauguration and related events at Washington, D. C. hotels and the favorable shift of Easter into the second quarter.
- Co issues downside guidance for FY17, sees EPS of $3.79-3.97 vs. $4.05 Capital IQ Consensus Estimate; sees total fee revenue of $3,175 million to $3,245 million. Marriott expects full year 2017 adjusted EBITDA could total $3,075 million to $3,175 million, a 3 to 6 percent increase compared to full year 2016 combined adjusted EBITDA of $2,987 million.
- For the full year 2017, Marriott expects comparable systemwide RevPAR on a constant dollar basis for the combined company will be flat to up 2 percent in North America. The company expects comparable systemwide RevPAR on a constant dollar basis for the combined company will increase 1 to 3 percent outside North America and 0.5 to 2.5 percent worldwide.
- The company expects investment spending in 2017 will total approximately $500 million to $700 million, including approximately $175 million for maintenance capital. Investment spending also includes other capital expenditures (including property acquisitions), new mezzanine financing and mortgage notes, contract acquisition costs, and equity and other investments. Assuming this level of investment spending and no asset sales, $1.5 billion to $2.0 billion could be returned to shareholders through share repurchases and dividends in 2017.
- Reports Q1 (Jan) earnings of $0.67 per share, excluding non-recurring items, $0.01 better than the Capital IQ Consensus of $0.66; revenues rose 45.2% year/year to $3.28 bln vs the $3.27 bln Capital IQ Consensus.
- Co issues upside guidance for Q2, sees EPS of $0.72-0.80, excluding non-recurring items, vs. $0.62 Capital IQ Consensus Estimate; sees Q2 revs of $3450-3600 vs. $3.21 bln Capital IQ Consensus Estimate